CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Béatrice Pignolet¹, Nicholas Schwab¹, Tilman Schneider-Hohendorf¹, Florence Bucciarelli¹, Damien Biotti¹, Delphine Averseng-Peaureaux¹, Olivier Outteryck¹, Jean-Claude Ongagna¹, Jérôme de Sèze¹, Bruno Brochet¹, Jean-Christophe Ouallet¹, Marc Debouverie¹, Sophie Pittion¹, Gilles Defer¹, Nathalie Derache¹, Patrick Hautecoeur¹, Ayman Tourbah¹, Pierre Labauge¹, Giovanni Castelnovo¹, Pierre Clavelou¹, Eric Berger¹, Jean Pelletier¹, Audrey Rico¹, Hélène Zéphir¹, David Laplaud¹, Sandrine Wiertlewski¹, William Camu¹, Eric Thouvenot¹, Olivier Casez¹, Thibault Moreau¹, Agnès Fromont¹, Sandra Vukusic¹, Caroline Papeix¹, Patrick Vermersch¹, Manuel Comabella¹, Christine Lebrun-Frenay¹, Heinz Wiendl¹, David Brassat²; BIONAT, SFSEP, and BEST-MS networks

Collaborators, Affiliations

Collaborators

BIONAT, SFSEP, and BEST-MS networks:
David Brassat, Béatrice Pignolet, Florence Bucciarelli, Nicholas Schwab, Tilman Schneider-Hohendorf, Heinz Wiendel, Manuel Comabella, Nicola Fissolo, Maria Martinez, Alexia di-Paolo, Florence Umuhoza, Lise Scandella, Sarah Exbrayat, David Brassat, Olivier Outteryck, Jean-Claude Ongagna, Jérôme de Sèze, Bruno Brochet, Jean-Christophe Ouallet, Marc Debouverie, Sophie Pittion, Gilles Defer, Nathalie Derache, Patrick Hautecoeur, Ayman Tourbah, Prof Pierre Labauge, Giovanni Castelnovo, Pierre Clavelou, Eric Berger, Jean Pelletier, Audrey Rico, Hélène Zéphir, David Laplaud, Sandrine Wiertlewski, Philippe Cabre, William Camu, Eric Thouvenot, Olivier Casez, M D Thibault Moreau, Agnès Fromont, Sandra Vukusic, Caroline Papeix, Catherine Lubetzki, Patrick Vermersch, Christine Lebrun-Frenay, Mikael Cohen, M D Lucien Rumbach, Olivier Heinzlef, Prof Jérôme de Sèze, Sophie Pittion, Hélène Zéphir, Olivier Anne, Bertrand Audoin, Caroline Bensa, Eric Berger, David Brassat, Prof Bruno Brochet, Bertrand Bourre, Philippe Cabre, Jean-Philippe Camdessanche, Olivier Casez, Giovanni Castelnovo, Prof Pierre Clavelou, Nicolas Collongues, Marc Coustans, Alain Créange, Md PhD Marc Debouverie, Nathalie Derache, Prof Gilles Defer, Dominique Dive, M D Gilles Edan, Agnès Fromont, Olivier Gout, Riadh Gouider, Jérôme Grimaud, Patrick Hautecoeur, Arnaud Kiatkoswki, Pierre Labauge, David Laplaud, Christine Lebrun-Frenay, Emmanuelle LePage, Romain Marignier, Thibault Moreau, Jean-Christophe Ouallet, Caroline Papeix, Jean Pelletier, Lucien Rumbach, Myriam Schluep, Pierrette Seeldrayers, Ilham Slassi Sennou, Bruno Stankoff, Frédéric Taithe, Ayman Tourbah, Eric Thouvenot, Patrick Vermersch, Sandra Vukusic, Sandrine Wiertlewski

Affiliations

¹ From the CHU Toulouse Purpan (B.P., F.B., D.B., D.A.-P., D.B.), Pôle Neurosciences; INSERM U1043-CNRS UMR 5282 (B.P., F.B., D.B.), Université Toulouse III, Centre de Physiopathologie Toulouse Purpan, France; University of Münster (N.S., T.S.-H., H.W.), Germany; University of Lille (O.O., H.Z., P.V.); Hôpital Civil (J.-C. Ongagna, J.d.S.), Strasbourg; CHU Pellegrin (B.B., J.-C. Ouallet), Bordeaux; CHU Nancy (M.D., S.P.); CHU Caen (G.D., N.D.); CH St Vincent (P.H.), GHICL, Lille; CHU Reims (A.T.); CHU Montpellier (P.L.); CHU Nîmes (G.C., W.C., O.C.); CHRU Clermont Ferrand (P.C.); CHU Besançon (E.B.); Aix Marseille University (J.P., A.R.), APHM, CHU Timone, Marseille; CHU Nantes (D.L., S.W.); CHU Grenoble (E.T.); CHU Dijon (T.M., A.F.); CHU Lyon (S.V.), Bron; Hôpital de la Salpêtrière (C.P.), Paris, France; Centre d'Esclerosi Múltiple de Catalunya (CEMCAT) (M.C.), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and CHU Nice (C.L.-F.), France.
² From the CHU Toulouse Purpan (B.P., F.B., D.B., D.A.-P., D.B.), Pôle Neurosciences; INSERM U1043-CNRS UMR 5282 (B.P., F.B., D.B.), Université Toulouse III, Centre de Physiopathologie Toulouse Purpan, France; University of Münster (N.S., T.S.-H., H.W.), Germany; University of Lille (O.O., H.Z., P.V.); Hôpital Civil (J.-C. Ongagna, J.d.S.), Strasbourg; CHU Pellegrin (B.B., J.-C. Ouallet), Bordeaux; CHU Nancy (M.D., S.P.); CHU Caen (G.D., N.D.); CH St Vincent (P.H.), GHICL, Lille; CHU Reims (A.T.); CHU Montpellier (P.L.); CHU Nîmes (G.C., W.C., O.C.); CHRU Clermont Ferrand (P.C.); CHU Besançon (E.B.); Aix Marseille University (J.P., A.R.), APHM, CHU Timone, Marseille; CHU Nantes (D.L., S.W.); CHU Grenoble (E.T.); CHU Dijon (T.M., A.F.); CHU Lyon (S.V.), Bron; Hôpital de la Salpêtrière (C.P.), Paris, France; Centre d'Esclerosi Múltiple de Catalunya (CEMCAT) (M.C.), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and CHU Nice (C.L.-F.), France. brassat.d@chu-toulouse.fr.

PMID: 27815407
DOI: 10.1212/WNL.0000000000003401

Clinical Trial

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Béatrice Pignolet et al. Neurology. 2016.

. 2016 Dec 6;87(23):2491-2494.

doi: 10.1212/WNL.0000000000003401. Epub 2016 Nov 4.

Authors

Collaborators

BIONAT, SFSEP, and BEST-MS networks:
David Brassat, Béatrice Pignolet, Florence Bucciarelli, Nicholas Schwab, Tilman Schneider-Hohendorf, Heinz Wiendel, Manuel Comabella, Nicola Fissolo, Maria Martinez, Alexia di-Paolo, Florence Umuhoza, Lise Scandella, Sarah Exbrayat, David Brassat, Olivier Outteryck, Jean-Claude Ongagna, Jérôme de Sèze, Bruno Brochet, Jean-Christophe Ouallet, Marc Debouverie, Sophie Pittion, Gilles Defer, Nathalie Derache, Patrick Hautecoeur, Ayman Tourbah, Prof Pierre Labauge, Giovanni Castelnovo, Pierre Clavelou, Eric Berger, Jean Pelletier, Audrey Rico, Hélène Zéphir, David Laplaud, Sandrine Wiertlewski, Philippe Cabre, William Camu, Eric Thouvenot, Olivier Casez, M D Thibault Moreau, Agnès Fromont, Sandra Vukusic, Caroline Papeix, Catherine Lubetzki, Patrick Vermersch, Christine Lebrun-Frenay, Mikael Cohen, M D Lucien Rumbach, Olivier Heinzlef, Prof Jérôme de Sèze, Sophie Pittion, Hélène Zéphir, Olivier Anne, Bertrand Audoin, Caroline Bensa, Eric Berger, David Brassat, Prof Bruno Brochet, Bertrand Bourre, Philippe Cabre, Jean-Philippe Camdessanche, Olivier Casez, Giovanni Castelnovo, Prof Pierre Clavelou, Nicolas Collongues, Marc Coustans, Alain Créange, Md PhD Marc Debouverie, Nathalie Derache, Prof Gilles Defer, Dominique Dive, M D Gilles Edan, Agnès Fromont, Olivier Gout, Riadh Gouider, Jérôme Grimaud, Patrick Hautecoeur, Arnaud Kiatkoswki, Pierre Labauge, David Laplaud, Christine Lebrun-Frenay, Emmanuelle LePage, Romain Marignier, Thibault Moreau, Jean-Christophe Ouallet, Caroline Papeix, Jean Pelletier, Lucien Rumbach, Myriam Schluep, Pierrette Seeldrayers, Ilham Slassi Sennou, Bruno Stankoff, Frédéric Taithe, Ayman Tourbah, Eric Thouvenot, Patrick Vermersch, Sandra Vukusic, Sandrine Wiertlewski

Affiliations

¹ From the CHU Toulouse Purpan (B.P., F.B., D.B., D.A.-P., D.B.), Pôle Neurosciences; INSERM U1043-CNRS UMR 5282 (B.P., F.B., D.B.), Université Toulouse III, Centre de Physiopathologie Toulouse Purpan, France; University of Münster (N.S., T.S.-H., H.W.), Germany; University of Lille (O.O., H.Z., P.V.); Hôpital Civil (J.-C. Ongagna, J.d.S.), Strasbourg; CHU Pellegrin (B.B., J.-C. Ouallet), Bordeaux; CHU Nancy (M.D., S.P.); CHU Caen (G.D., N.D.); CH St Vincent (P.H.), GHICL, Lille; CHU Reims (A.T.); CHU Montpellier (P.L.); CHU Nîmes (G.C., W.C., O.C.); CHRU Clermont Ferrand (P.C.); CHU Besançon (E.B.); Aix Marseille University (J.P., A.R.), APHM, CHU Timone, Marseille; CHU Nantes (D.L., S.W.); CHU Grenoble (E.T.); CHU Dijon (T.M., A.F.); CHU Lyon (S.V.), Bron; Hôpital de la Salpêtrière (C.P.), Paris, France; Centre d'Esclerosi Múltiple de Catalunya (CEMCAT) (M.C.), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and CHU Nice (C.L.-F.), France.
² From the CHU Toulouse Purpan (B.P., F.B., D.B., D.A.-P., D.B.), Pôle Neurosciences; INSERM U1043-CNRS UMR 5282 (B.P., F.B., D.B.), Université Toulouse III, Centre de Physiopathologie Toulouse Purpan, France; University of Münster (N.S., T.S.-H., H.W.), Germany; University of Lille (O.O., H.Z., P.V.); Hôpital Civil (J.-C. Ongagna, J.d.S.), Strasbourg; CHU Pellegrin (B.B., J.-C. Ouallet), Bordeaux; CHU Nancy (M.D., S.P.); CHU Caen (G.D., N.D.); CH St Vincent (P.H.), GHICL, Lille; CHU Reims (A.T.); CHU Montpellier (P.L.); CHU Nîmes (G.C., W.C., O.C.); CHRU Clermont Ferrand (P.C.); CHU Besançon (E.B.); Aix Marseille University (J.P., A.R.), APHM, CHU Timone, Marseille; CHU Nantes (D.L., S.W.); CHU Grenoble (E.T.); CHU Dijon (T.M., A.F.); CHU Lyon (S.V.), Bron; Hôpital de la Salpêtrière (C.P.), Paris, France; Centre d'Esclerosi Múltiple de Catalunya (CEMCAT) (M.C.), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and CHU Nice (C.L.-F.), France. brassat.d@chu-toulouse.fr.

PMID: 27815407
DOI: 10.1212/WNL.0000000000003401

No abstract available

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Collaborators

Affiliations

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Authors

Collaborators

Affiliations

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical